Scinai Immunotherapeutics Ltd ADR (SCNI)

$1.58 +0.04 (2.60%)
Market Cap 1.54M
Revenue (ttm) 660,000.00
Net Income (ttm) 4.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 727.27%
Debt to Equity Ratio 0.04
Volume 66,300
Avg Vol 1,358,356
Day's Range N/A - N/A
Shares Out 1.00M
Stochastic %K 52%
Beta 1.83
Analysts Strong Buy
Price Target $8.00

Company Profile

Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufac...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 930 2529
Fax: 972 8 930 2531
Address:
Jerusalem BioPark, 2nd floor Hadassah Ein Kerem Campus, Jerusalem, Israel
HighestC
HighestC Sep. 11 at 8:09 PM
$SCNI i see you my boi 🧏⏳
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 11 at 1:20 PM
If there is one thing I learned in the last 5 years trading full time is that most ISRAEL tickers never hold gains. You better lock profits on the way up and never look back. Careful out there guys, they are setting traps. $SLXN $SPRC $IMCC $PRFX $SCNI
1 · Reply
HighestC
HighestC Sep. 11 at 12:08 PM
$SCNI FENG grant news and we go 300%-1000% in this market
0 · Reply
JimBull
JimBull Sep. 11 at 11:41 AM
$WLDS yesterday and $SLXN today, both from Israel ! the rest Israel stocks on watch : $JFBR $SPRC $SCNI
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 11 at 11:32 AM
After $SLXN watch $SPRC $IMCC $PRFX $SCNI
0 · Reply
howweroll11
howweroll11 Sep. 9 at 2:14 AM
$SCNI lol clown has been saying the same shit since $1.85 quit falling for these pumpers
0 · Reply
TheFlash
TheFlash Sep. 8 at 11:53 PM
$SCNI On the #dailydouble list. How many of these bottomed out low floaters did we see double today? 3,4,5 ? 👀🚀
0 · Reply
DocG67
DocG67 Sep. 8 at 10:26 AM
$SCNI
0 · Reply
StockFlips
StockFlips Sep. 6 at 12:07 PM
$SCNI $PTIX $THAR
0 · Reply
CrumbEater
CrumbEater Sep. 3 at 5:51 PM
$SCNI positive news and hasn't moved a bit
0 · Reply
Latest News on SCNI
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

Sep 2, 2025, 7:30 AM EDT - 10 days ago

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Jul 29, 2025, 7:15 AM EDT - 6 weeks ago

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Jun 12, 2025, 8:00 AM EDT - 3 months ago

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Jun 5, 2025, 9:00 AM EDT - 3 months ago

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

May 30, 2025, 7:00 AM EDT - 3 months ago

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

Scinai Announces Annual Financial Results for 2024

May 7, 2025, 4:01 PM EDT - 4 months ago

Scinai Announces Annual Financial Results for 2024

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

May 1, 2025, 7:00 AM EDT - 4 months ago

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Mar 27, 2025, 9:25 AM EDT - 6 months ago

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

Mar 17, 2025, 7:00 AM EDT - 6 months ago

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Mar 5, 2025, 7:30 AM EST - 6 months ago

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Jan 6, 2025, 7:31 AM EST - 8 months ago

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Dec 16, 2024, 9:25 AM EST - 9 months ago

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Dec 5, 2024, 8:25 AM EST - 10 months ago

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 27, 2024, 8:00 AM EST - 10 months ago

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Nov 22, 2024, 7:15 AM EST - 10 months ago

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Oct 31, 2024, 6:59 AM EDT - 11 months ago

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Sep 9, 2024, 11:12 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Aug 29, 2024, 6:31 AM EDT - 1 year ago

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Aug 20, 2024, 2:28 PM EDT - 1 year ago

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Aug 20, 2024, 9:30 AM EDT - 1 year ago

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Jul 15, 2024, 12:31 PM EDT - 1 year ago

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Jul 8, 2024, 8:14 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Jul 3, 2024, 9:32 AM EDT - 1 year ago

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:12 AM EDT - 1 year ago

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Jun 13, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

Jun 7, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

May 24, 2024, 4:01 PM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

May 15, 2024, 4:01 PM EDT - 1 year ago

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

May 6, 2024, 9:21 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Scinai leadership to attend BIO-Europe Spring 2024

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Scinai leadership to attend BIO-Europe Spring 2024

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

Feb 29, 2024, 8:45 AM EST - 1 year ago

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Feb 13, 2024, 7:00 AM EST - 1 year ago

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Jan 25, 2024, 10:26 AM EST - 1 year ago

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Jan 4, 2024, 4:01 PM EST - 1 year ago

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Jan 4, 2024, 6:15 AM EST - 1 year ago

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Dec 29, 2023, 9:21 AM EST - 1 year ago

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9

Dec 27, 2023, 7:15 AM EST - 1 year ago

Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9

Scinai Announces Promising Results in a Psoriatic Human Skin Model

Dec 12, 2023, 7:26 AM EST - 1 year ago

Scinai Announces Promising Results in a Psoriatic Human Skin Model

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

Dec 11, 2023, 8:11 AM EST - 1 year ago

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031

Nov 29, 2023, 9:25 AM EST - 1 year ago

European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule

Nov 20, 2023, 7:30 AM EST - 1 year ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule

Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit

Nov 6, 2023, 7:30 AM EST - 2 years ago

Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit

HighestC
HighestC Sep. 11 at 8:09 PM
$SCNI i see you my boi 🧏⏳
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 11 at 1:20 PM
If there is one thing I learned in the last 5 years trading full time is that most ISRAEL tickers never hold gains. You better lock profits on the way up and never look back. Careful out there guys, they are setting traps. $SLXN $SPRC $IMCC $PRFX $SCNI
1 · Reply
HighestC
HighestC Sep. 11 at 12:08 PM
$SCNI FENG grant news and we go 300%-1000% in this market
0 · Reply
JimBull
JimBull Sep. 11 at 11:41 AM
$WLDS yesterday and $SLXN today, both from Israel ! the rest Israel stocks on watch : $JFBR $SPRC $SCNI
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Sep. 11 at 11:32 AM
After $SLXN watch $SPRC $IMCC $PRFX $SCNI
0 · Reply
howweroll11
howweroll11 Sep. 9 at 2:14 AM
$SCNI lol clown has been saying the same shit since $1.85 quit falling for these pumpers
0 · Reply
TheFlash
TheFlash Sep. 8 at 11:53 PM
$SCNI On the #dailydouble list. How many of these bottomed out low floaters did we see double today? 3,4,5 ? 👀🚀
0 · Reply
DocG67
DocG67 Sep. 8 at 10:26 AM
$SCNI
0 · Reply
StockFlips
StockFlips Sep. 6 at 12:07 PM
$SCNI $PTIX $THAR
0 · Reply
CrumbEater
CrumbEater Sep. 3 at 5:51 PM
$SCNI positive news and hasn't moved a bit
0 · Reply
NetworkNewsWire
NetworkNewsWire Sep. 2 at 4:35 PM
BioMedNewsBreaks — $SCNI Reports First-Half 2025 Results and Strengthened Cash Position https://ibn.fm/q3nyE
0 · Reply
Richard_Roma
Richard_Roma Aug. 30 at 4:02 PM
$SCNI Sept 11th date is a good way to describe this bioturd
1 · Reply
BelugaPicks
BelugaPicks Aug. 29 at 5:24 PM
$SCNI there is an update for the 12m funding.deadline is now 8 November 2025
1 · Reply
CometaMan
CometaMan Aug. 29 at 3:02 PM
$SCNI good 😊 entry price $1.50 or less.
0 · Reply
Rakanss1
Rakanss1 Aug. 29 at 1:42 PM
$SCNI What happen
0 · Reply
BelugaPicks
BelugaPicks Aug. 29 at 7:33 AM
$SCNI If it’s extended by another week, we should hear something next week. The deadline, as discussed earlier, is September 11.
0 · Reply
Wakaas93
Wakaas93 Aug. 28 at 2:34 PM
$SCNI In
0 · Reply
luckysupernova
luckysupernova Aug. 28 at 12:21 AM
$SCNI in down trend, support zones and triple dip after bounce from 52 week low recently.
0 · Reply
CrumbEater
CrumbEater Aug. 27 at 8:17 PM
$SCNI waiting for this news...
0 · Reply
OATbro
OATbro Aug. 27 at 12:52 AM
$SCNI Before 9/11 ! Wait for u 👍
0 · Reply
coldfacts
coldfacts Aug. 26 at 7:31 PM
$SCNI down to 1.40s we go
0 · Reply
Awkward_Assistance70
Awkward_Assistance70 Aug. 26 at 2:05 PM
$SCNI FENG News regarding the warrant will be published at any time before September 11.
3 · Reply